Every website has a story, and your visitors want to hear yours. This space is a great opportunity to give a full background on who you are, what your team does and what your site has to offer. Double click on the text box to start editing your content and make sure to add all the relevant details you want site visitors to know.

If you’re a business, talk about how you started and share your professional journey. Explain your core values, your commitment to customers and how you stand out from the crowd. Add a photo, gallery or video for even more engagement.

PyroTIMER is a universal, licensable T cell enhancement platform that remodels the tumor microenvironment, preventing T cell suppression while significantly improving persistence and cytotoxicity.

PyroTIMER
Cell Therapy Enhancement Platform

How PyroTIMER Enhances Cell Therapies

TIME Remodeling: Overcoming Immunosuppressive Barriers

Blocks key immunosuppressive pathways that inhibit T cell function, allowing CAR-T/TCR-T cells to remain active in the tumor microenvironment.
Enhances T cell trafficking and infiltration, ensuring deeper tumor penetration and superior anti-tumor activity.

Delays Exhaustion & Improves Persistence

PyroTIMER reduces exhaustion by >80%, extending the functional lifespan of T cells.
In preclinical models, PyroTIMER-enhanced CAR-T cells remain active for 2-3x longer compared to conventional CAR-T cells.

Increases Cytotoxicity & Tumor Clearance

3x improved tumor killing in vitro and in vivo across multiple tumor types, including solid and hematological cancers.
Demonstrates enhanced T cell activation , ensuring sustained anti-tumor effects.

Better Safety Profile: Eliminates CRS & Off-Target Toxicity

No cytokine release syndrome (CRS) or off-tumor toxicity observed in preclinical models.
PyroTIMER improves T cell function without triggering excessive inflammatory responses, making it a safer enhancement for adoptive cell therapy.

Licensable & Adaptable Across CAR/TCR-T Platforms

Compatible with FDA-approved CAR-T therapies and next-generation TCR-based therapies.
Licensable to cell therapy companies, CDMOs, and CROs, allowing for seamless integration into existing programs.
Companies can secure licensing rights for specific tumor antigens or indications to differentiate their therapies in a competitive market.

Licensable Platform
PyroTIMER

PyroTIMER Licensable Platform & Strategic Partnerships

PyroTIMER is a universal T cell enhancement platform designed to improve the persistence, cytotoxicity, and durability of CAR-T and TCR-T cell therapies. By overcoming the immunosuppressive tumor immune microenvironment (TIME), PyroTIMER enhances therapeutic efficacy across hematologic malignancies and solid tumors.

Strategic Licensing & Partnerships

PyroTIMER is actively being integrated into approved and late-stage cell therapy programs, with a focus on clinically validated antigen targets. Our licensing model prioritizes FDA-approved therapies, ongoing clinical trials, and early-stage assets, ensuring broad clinical impact.

Hematologic Malignancies

PyroTIMER is being incorporated into leading CAR-T and TCR-T programs targeting well-established hematologic malignancies:

CD19 CAR-T Therapies: ALL, CLL, NHL, DLBCL, Mantle Cell Lymphoma
BCMA CAR-T Therapies: Multiple Myeloma
CD30 CAR-T Therapies: Hodgkin’s Lymphoma
CD33/CD123 FLT3 CAR-T Therapies: Acute Myeloid Leukemia
TCR-Based Therapies: T-Cell Lymphomas

Validation: PyroTIMER™ improves tumor clearance in CD19+ CAR-T models and significantly reduces T cell exhaustion markers.

Solid Tumors

PyroTIMER expands T cell therapy efficacy into solid tumors, targeting well-characterized antigens with clinical validation:

Breast Cancer: HER2, NY-ESO-1 (TCR)
Lung Cancer: HER2, NY-ESO-1 (TCR)
Glioblastoma: EGFRvIII
Pancreatic Cancer: Mesothelin
Colorectal Cancer: CEA
Liver Cancer: GPC3
Prostate Cancer: PSMA
Esophageal Cancer: MUC1
Neuroblastoma: GD2

Impact: PyroTIMER demonstrated 3x improved tumor killing in NY-ESO-1 TCR-T models (breast, lung, synovial carcinoma) and delayed exhaustion in immunosuppressive environments.

Key Benefits of PyroTIMER Integration

Enhanced Tumor Clearance → Over 3x increase in tumor control compared to conventional CARs
Reduced T Cell Exhaustion → Over 80% reduction exhaustion
Improved Persistence → Durable T cell function in solid tumors
IND-Ready in 6–8 Months → Accelerated preclinical-to-clinical transition
Licensable Technology → Target-specific & indication-specific licensing available

PyroTIMER is out-licensed to leading cell therapy companies, CDMOs, and CROs to drive the next wave of differentiated, clinically validated cell therapies.

Interested in integrating PyroTIMER into your CAR-T/TCR-T programs?

📩 Contact us to explore licensing and partnership opportunities